



# PRESBIA COMPANY PROFILE

## Presbia Company Overview

Presbia is an ophthalmologic device company focused on the commercialization of the presbyopia-correcting Flexivue Microlens<sup>®</sup>—an innovative solution for the common age-related loss of the ability to read or focus on near objects. Using a femtosecond laser, the surgeon creates a pocket in the cornea and implants the Flexivue Microlens<sup>®</sup>. This procedure yields a safe, effective, permanent yet reversible solution for presbyopia.

The Flexivue Microlens<sup>®</sup> has been in development since 2001. Through the merger of Visitome and PresbiTech, Presbia was created in 2008 and the company formally introduced the lens to the medical community at the 2009 Congress of the European Society of Cataract and Refractive Surgery in Barcelona.

Presbia's Flexivue Microlens<sup>®</sup> has received the CE Mark for the European Economic Area, allowing the lens to be commercially available in 40 countries across Europe and Latin America. Presbia is an ISO 13485:2003 CMDCAS approved company. Over 500 patients have had the lens implanted for more than three years since 2004, reporting over 90% satisfaction in the European Economic Area.

Presbia is led by an experienced management team with a track record of leading several successful technology ventures and also in advancing the art and science of ophthalmic medicine. Presbia has also assembled a team of internationally-renowned ophthalmic surgeons to serve on its Medical Advisory Board.

## About Presbyopia

Presbyopia is the gradual loss of near vision affecting adults over the age of 35 causing difficulty with everyday work and life activities such as reading computer screens, hand-held devices and printed material.

**Prevalence:** While medical experts continue to debate the precise cause of presbyopia, its prevalence remains unquestioned. Since presbyopia is age-related, its prevalence is directly proportionate to the size of the world's aging population. Currently, there are approximately 1.6 billion adults worldwide affected by presbyopia, and within the next 10 years, that number is expected to increase by 31 percent.

**Treatment:** Corrective lenses (either reading glasses or contact lenses) are the most common treatment for presbyopia. Although useful, these solutions are inconvenient and require the patient to continually adjust for near and distance vision. Various surgical treatments are available, including LASIK procedures, the use of off-label cataract-type lenses, and other implantable devices. However, unlike Presbia's Flexivue Microlens<sup>®</sup>, these procedures do not offer a reversible option, can deliver less than satisfactory vision, and may alter the patient's appearance.

**Market:** The market for a new surgical treatment of presbyopia is substantial. Presbia estimates that, allowing for economic and social factors, approximately 11 percent of the world's population qualify as candidates for the Flexivue Microlens<sup>®</sup> procedure. Ophthalmic industry newsletter *Market Scope*, found that the annual number of presbyopia-correcting surgeries has the potential to increase from fewer than 400,000 today to approximately 3.8 million procedures by 2020. In addition, spending on presbyopia-related surgery could reach \$1.1 billion within four years.

Lifestyle needs, such as a growing dependency on technology, will drive the demand for corrective surgical options for presbyopia.

The aging population, the increase in the average retirement age, a growing affluent class with more disposable income, and the increased access to advanced eye care all contribute to the demand for a solution to correct presbyopia.

### **The Presbia's Flexivue Microlens<sup>®</sup> Solution**

Presbia's Flexivue Microlens<sup>®</sup>—just three millimeters in diameter and approximately 15 microns in edge thickness (a fraction of the thickness of a human hair)—is made of hydrophilic polymer, similar to the material used for intraocular lenses for the past 20 years.

For implantation, the surgeon uses a femtosecond laser, the same type of laser now widely used for LASIK surgery, to create a pocket in the stroma of the patient's cornea. Using Presbia's proprietary insertion tool, the lens is placed into the pocket, which then seals itself, holding the lens in place in the center of the visual axis.

The procedure typically takes less than 10 minutes, is usually performed on the non-dominant eye (in order to leave distance vision unaffected), and requires only topical anesthesia. To an observer, the tiny, clear lens makes no noticeable change to the appearance of the patient's eye, and within a couple of days the patient's vision is recovered. The Flexivue Microlens<sup>®</sup> can stay in place permanently, or can be easily and safely removed—if, for example, the patient's presbyopia advances and a stronger prescription is required.

Presbia's Flexivue Microlens<sup>®</sup> surgery can be performed at the more than 4,500 laser surgery centers already in place worldwide. There is a large global pool of refractive surgeons who can easily be trained by Presbia on the technique to create the pocket in the cornea and insert the Flexivue Microlens<sup>®</sup>.

### **Features & Benefits**

#### **Safety**

- Optically reversible
- No permanent loss of corneal tissue, unlike LASIK
- Biocompatible with the cornea
- Allows for normal corneal metabolism
- Flexibility to remove lens if prescription upgrade is needed or new technology becomes available

#### **Improved Vision**

- Sharp and clear near vision
- Minor or no distance visual acuity change
- Quick visual recovery, typically within a few days

#### **Satisfaction**

- Improves lifestyle, ending the need for reading glasses
- Cosmetically appealing, the Flexivue Microlens<sup>®</sup> is invisible to the eye

## Presbia Medical Advisory Board

- **Prof. Ioannis Pallikaris, M.D.**—Presbia Medical Advisory Board Chair and Director of the Institute of Vision and Optics of the University of Crete. Prof. Pallikaris, widely regarded as the “father” of LASIK surgery, is currently overseeing post market surveillance of the Flexivue Microlens® and beginning recruitment for surgeon training.
- **Jorge Alió, M.D.**—Founder and Medical Director of the Instituto Oftalmológico de Alicante (now Vissum Corp.) in Spain. Dr. Alió is also the Founder of the Fundación Jorge Alió for the Prevention of Blindness and is recognized as leading authority in the field of refractive surgery.
- **Kerry Assil, M.D.**—Founder and Medical Director of the Assil Eye Institute in Beverly Hills. Dr. Assil is one of the world's foremost experts in refractive surgery.
- **Marco Fantozzi, M.D.**— Presbia-certified ophthalmologic surgeon who has performed more than 10,000 refractive operations throughout his distinguished career.
- **Michael Gordon, M.D.**—Board-certified ophthalmologist and Founder of the Gordon Binder Vision Institute in San Diego. Dr. Gordon was also a founding board member of the International LASIK Institute, and was the first surgeon in the U.S. to use the Summit excimer laser to correct nearsightedness. He has lectured and taught excimer laser techniques all over the world.
- **Ronald Krueger, M.D.** - Medical Director of Refractive Surgery at the Cleveland Clinic Cole Eye Institute and Professor of Ophthalmology at Lerner College of Medicine at Case Western Reserve University.
- **Gustavo Tamayo, M.D.** —Director of the Bogotá Laser Refractive Institute in Bogotá, Colombia, is a leader in the field of refractive surgery, especially in the treatment of presbyopia. He holds several patents for the treatment of presbyopia and irregular astigmatism as well as for phacoemulsification surgical procedures.

## Presbia Management

- **Zohar Loshitzer**—Chief Executive Officer. Mr. Loshitzer is a principal at Orchard Capital Corporation, Presbia’s private equity backer. Loshitzer has led the development of a number of successful technology-related companies, including Universal Telecom Services, J2 Global Communications and Life Alert Emergency Response.
- **Vladimir Feingold**—Chief Technology Officer. Mr. Feingold was the Founder and CEO of Visitome and Biovision AG, and joined Presbia in 2008 as part of Visitome merger. He holds more than 30 patents on advanced ocular surgical devices, lens systems and related technologies.
- **Vipul Shah**—Director of Operations. Mr. Shah has more than 10 years experience in manufacturing, operations management and manufacturing systems in the medical device and optical industries. He was Director of U.S. Manufacturing for Visitome and joined Presbia in 2008.

Contact: Theresa Matson

Tel: +1-323-860-9544

Email: [theresa@presbia.com](mailto:theresa@presbia.com)

**Note:** The Flexivue Microlens® and related medical procedures are not available in the United States and have not been evaluated or approved by the U.S. Food and Drug Administration.

###